Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports
Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports
Source link
Similar Posts
Nifty seen moving rangebound amid sector rotation; cautious optimism advised
After a strong move in the week before this one, the Nifty spent the last five sessions largely consolidating in a very defined range. The markets traded with a weak underlying bias and lost ground gradually over the past few days; however, the drawdown remained quite measured and within the expected range. As the markets…
The K-Shaped Economy Spells Trouble – Fat Tail Daily
With the US government shutdown nearing resolution — after Democrats appeared to cave — data nerds and quants can breathe a sigh of relief. For the past month, the federal shutdown has halted almost all economic data. Many on Wall Street, as well as Fed Chair J. Powell, have described this period as ‘flying blind’….
Speb Adhesives shares to debut today. GMP hints at muted gains
Speb Adhesives will make its NSE SME debut on December 8 after closing a 33.73 crore IPO that saw moderate subscription and steady institutional interest. Ahead of the listing, the grey market premium is subdued, indicating a restrained pre-listing sentiment. GMP tends to be less predictive in SME issues where liquidity, sectoral positioning and financial…
Boston Scientific Corporation (BSX) Wells Fargo 2024 Healthcare Conference (Transcript)
Boston Scientific Corporation (NYSE:BSX) Wells Fargo 2024 Healthcare Conference September 4, 2024 8:00 AM ET Company Participants Brad Sutton – Chief Medical Officer, AF SolutionsJon Monson – SVP, IRMichael F. Mahoney – Chairman and CEO Conference Call Participants Lawrence Biegelsen – Wells Fargo Securities Lawrence Biegelsen Okay. Good morning and welcome to the 2024 Wells…
Got $3,000? 2 Monster Growth Stocks to Buy Right Now Without Hesitation
Image source: Getty Images The year 2025 could be one of artificial intelligence (AI) and crypto stocks. Companies that have harnessed this growth potential could see a boost in demand as lower interest rates and economic recovery drive technology spending by companies and customers. The AI boom Nvidia saw was the experimental phase where companies…
